Progress of new drugs on relapsed/refractory peripheral T-cell lymphoma

doi:10.3760/cma.j.cn371439-20200507-00029

Abstract

Abstract:

Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous diseases originating from post-thymic T-cells, with poor prognosis using traditional therapy, especially in patients with relapsed/refractory PTCLs (r/rPTCLs). In recent years, a variety of new anti-tumor drugs have emerged in the treatment of r/rPTCLs, including different types of enzyme inhibitors, monoclonal antibodies, immunomodulators and immune checkpoint inhibitors, which have been proved to be effective. The discovery and clinical application of new drugs are expected to improve the outcomes of the diseases.

Key words: Lymphoma,T-cell,peripheral, Recurrence, Therapy, New drugs

Zhao Ke, Wang Huaqing. Progress of new drugs on relapsed/refractory peripheral T-cell lymphoma[J]. Journal of International Oncology, 2020, 47(6): 321-326.

References 47

[1]	李小秋, 李甘地, 高子芬, 等. 中国淋巴瘤亚型分布: 国内多中心性病例10 002例分析[J]. 诊断学理论与实践, 2012,11(2):111-115. DOI: 10.3969/j.issn.1671-2870.2012.02.006.
[2]	Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol, 2008,26(25):4124-4130. DOI: 10.1200/JCO.2008.16.4558. doi: 10.1200/JCO.2008.16.4558 pmid: 18626005
[3]	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016,127(20):2375-2390. DOI: 10.1182/blood-2016-01-643569. doi: 10.1182/blood-2016-01-643569 pmid: 26980727
[4]	Abouyabis AN, Shenoy PJ, Lechowicz MJ, et al. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States[J]. Leuk Lymphoma, 2008,49(11):2099-2107. DOI: 10.1080/10428190802455867. doi: 10.1080/10428190802455867 pmid: 19021052
[5]	O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivo-tal phase Ⅱ BELIEF (CLN-19) study[J]. J Clin Oncol, 2015,33(23):2492-2499. DOI: 10.1200/JCO.2014.59.2782. doi: 10.1200/JCO.2014.59.2782 pmid: 26101246
[6]	Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase Ⅱ study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy[J]. J Clin Oncol, 2012,30(6):631-636. DOI: 10.1200/JCO.2011.37.4223. doi: 10.1200/JCO.2011.37.4223
[7]	Mehta-Shah N, Moskowitz AJ, Lunning M, et al. A phase Ⅰb/Ⅱa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas[J]. Blood, 2016,128(22):2991. DOI: 10.1182/blood.V128.22.2991.2991. doi: 10.1182/blood.V128.22.2991.2991
[8]	Strati P, Chihara D, Oki Y, et al. A phase Ⅰ study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma[J]. Haematologica, 2018,103(9):e416-e418. DOI: 10.3324/haematol.2018.187617. doi: 10.3324/haematol.2018.187617 pmid: 29622656
[9]	Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase Ⅱ study of chidamide in relapsed or refractory peripheral T-cell lymphoma[J]. Ann Oncol, 2015,26(8):1766-1771. DOI: 10.1093/annonc/mdv237. doi: 10.1093/annonc/mdv237 pmid: 26105599
[10]	Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China[J]. J Hematol Oncol, 2017,10(1):69. DOI: 10.1186/s13045-017-0439-6. doi: 10.1186/s13045-017-0439-6 pmid: 28298231
[11]	Huang D, Song TL, Nairismägi ML, et al. Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma[J]. Br J Haematol, 2020,189(4):731-744. DOI: 10.1111/bjh.16435. doi: 10.1111/bjh.16435 pmid: 32004387
[12]	Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase Ⅱ study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma[J]. Ann Oncol, 2017,28(9):2169-2178. DOI: 10.1093/annonc/mdx289. doi: 10.1093/annonc/mdx289 pmid: 28633365
[13]	Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase Ⅰ trial and preclinical models of T-cell lymphoma[J]. Blood, 2018,131(8):888-898. DOI: 10.1182/blood-2017-08-802470. doi: 10.1182/blood-2017-08-802470 pmid: 29233821
[14]	Barr PM, Li H, Spier C, et al. Phase Ⅱ intergroup trial of Alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108[J]. J Clin Oncol, 2015,33(21):2399-2404. DOI: 10.1200/JCO.2014.60.6327. doi: 10.1200/JCO.2014.60.6327 pmid: 26077240
[15]	O'Connor OA, Özcan M, Jacobsen ED, et al. Randomized phase Ⅲ study of Alisertib or investigator's choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma[J]. J Clin Oncol, 2019,37(8):613-623. DOI: 10.1200/JCO.18.00899. doi: 10.1200/JCO.18.00899 pmid: 30707661
[16]	Carlo-Stella C, Delarue R, Scarfo L, et al. A first-in-human study of tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in patients with relapsed/refractory hematologic malignancies: results from the European study[J]. Clin Lymphoma Myeloma Leuk, 2020,20(2):78-86. DOI: 10.1016/j.clml.2019.10.013. doi: 10.1016/j.clml.2019.10.013 pmid: 31761713
[17]	Horwitz SM, Feldman TA, Hess BT, et al. The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma[J]. Blood, 2018,132(suppl 1):1001. DOI: 10.1182/blood-2018-99-119944. doi: 10.1182/blood-2018-99-119944
[18]	Gambacorti Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients[J]. J Natl Cancer Inst, 2014, 106(2):djt378. DOI: 10.1093/jnci/djt378.
[19]	Maruyama D, Tsukasaki K, Uchida T, et al. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma[J]. Ann Hematol, 2019,98(1):131-142. DOI: 10.1007/s00277-018-3418-2. doi: 10.1007/s00277-018-3418-2 pmid: 29974231
[20]	O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study[J]. J Clin Oncol, 2011,29(9):1182-1189. DOI: 10.1200/JCO.2010.29.9024. doi: 10.1200/JCO.2010.29.9024
[21]	Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas[J]. Blood, 2004,103(8):2920-2924. DOI: 10.1182/blood-2003-10-3389. doi: 10.1182/blood-2003-10-3389 pmid: 15070664
[22]	Kim SJ, Kim K, Park Y, et al. Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity[J]. Invest New Drugs, 2012,30(1):368-375. DOI: 10.1007/s10637-010-9523-2. doi: 10.1007/s10637-010-9523-2 pmid: 20734108
[23]	Ogura M, Ishida T, Hatake K, et al. Multicenter phase Ⅱ study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma[J]. J Clin Oncol, 2014,32(11):1157-1163. DOI: 10.1200/JCO.2013.52.0924. doi: 10.1200/JCO.2013.52.0924
[24]	Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin[J]. Blood, 2014,123(20):3095-3100. DOI: 10.1182/blood-2013-12-542142. doi: 10.1182/blood-2013-12-542142
[25]	Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase Ⅱ study[J]. J Clin Oncol, 2012,30(18):2190-2196. DOI: 10.1200/JCO.2011.38.0402. doi: 10.1200/JCO.2011.38.0402
[26]	Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma[J]. Blood, 2017,130(25):2709-2717. DOI: 10.1182/blood-2017-05-780049. doi: 10.1182/blood-2017-05-780049 pmid: 28974506
[27]	Toumishey E, Prasad A, Dueck G, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma[J]. Cancer, 2015,121(5):716-723. DOI: 10.1002/cncr.29103. doi: 10.1002/cncr.29103 pmid: 25355245
[28]	Morschhauser F, Fitoussi O, Haioun C, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial[J]. Eur J Cancer, 2013,49(13):2869-2876. DOI: 10.1016/j.ejca.2013.04.029. doi: 10.1016/j.ejca.2013.04.029
[29]	Lunning MA, Ruan J, Nair S, et al. A phase Ⅰ/Ⅱ trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: phase Ⅰ results[J]. J Clin Oncol, 2014,32(15_suppl):8582. DOI: 10.1200/jco.2014.32.15_suppl.8582. doi: 10.1200/jco.2014.32.15_suppl.8582
[30]	Hopfinger G, Nösslinger T, Lang A, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase Ⅰ/Ⅱ trial[J]. Ann Hematol, 2014,93(3):459-462. DOI: 10.1007/s00277-014-2009-0. doi: 10.1007/s00277-014-2009-0
[31]	Liu X, Shang Y, Li L, et al. Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China[J]. Cancer Manag Res, 2019,11:8277-8284. DOI: 10.2147/CMAR.S215585. doi: 10.2147/CMAR.S215585 pmid: 31571985
[32]	Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial[J]. Lancet Oncol, 2020,21(4):541-550. DOI: 10.1016/S1470-2045(20)30023-1. doi: 10.1016/S1470-2045(20)30023-1 pmid: 32192573
[33]	Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phaseⅡ checkmate 436 study[J]. J Clin Oncol, 2019,37(33):3081-3089. DOI: 10.1200/JCO.19.01492. doi: 10.1200/JCO.19.01492 pmid: 31398081
[34]	Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial[J]. Lancet Oncol, 2019,20(2):239-253. DOI: 10.1016/S1470-2045(18)30765-4. doi: 10.1016/S1470-2045(18)30765-4 pmid: 30660609
[35]	Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer[J]. N Engl J Med, 2019,381(21):2020-2031. DOI: 10.1056/NEJMoa1910231. doi: 10.1056/NEJMoa1910231 pmid: 31562796
[36]	Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ⅰb study[J]. J Clin Oncol, 2016,34(23):2698-2704. DOI: 10.1200/JCO.2015.65.9789. doi: 10.1200/JCO.2015.65.9789 pmid: 27269947
[37]	Bennani NN, Pederson LD, Atherton P, et al. A phase Ⅱ study of nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma[J]. Blood, 2019,134(suppl_1):467. DOI: 10.1182/blood-2019-126194. doi: 10.1182/blood-2019-126194
[38]	Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase[J]. Blood, 2017,129(17):2437-2442. DOI: 10.1182/blood-2016-12-756841. doi: 10.1182/blood-2016-12-756841 pmid: 28188133
[39]	Tao R, Fan L, Song Y, et al. Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): a multicenter, single-arm, phase 2 trial (ORIENT-4)[J]. J Clin Oncol, 2019,15_suppl::7504. DOI: 10.1200/jco.2019.37.15_suppl.7504.
[40]	Shi YK, Wu JQ, Wang Z, et al. The efficacy and safety of Geptanolimab (GB226) in patients with relapsed/refractory peripheral T cell lymphoma (PTCL): a multicenter, open-label, single-arm, phase 2 trial[C/OL]// AACR Annual Meeting 2020: Session VCTPL04-Immunotherapy clinical trials 2. America, 2020[2020-04-28]. https://www.abstractsonline.com/pp8/#!/9045/presentation/10750.
[41]	Hong X, Song Y, Huang H, et al. Pralatrexate in Chinese patients with relapsed or refractory peripheral T-cell lymphoma: a single-arm, multicenter study[J]. Target Oncol, 2019,14(2):149-158. DOI: 10.1007/s11523-019-00630-y. doi: 10.1007/s11523-019-00630-y pmid: 30904980
[42]	Maruyama D, Nagai H, Maeda Y, et al. Phase Ⅰ/Ⅱ study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma[J]. Cancer Sci, 2017,108(10):2061-2068. DOI: 10.1111/cas.13340. doi: 10.1111/cas.13340 pmid: 28771889
[43]	Amengual JE, Lichtenstein R, Lue J, et al. A phase Ⅰ study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma[J]. Blood, 2018,131(4):397-407. DOI: 10.1182/blood-2017-09-806737. doi: 10.1182/blood-2017-09-806737 pmid: 29141948
[44]	Farhan A, Chong EA, Schuster SJ, et al. Bexarotene in patients with peripheral T-cell lymphomas: results of a retrospective study[J]. Clin Lymphoma Myeloma Leuk, 2019,19(2):109-115. DOI: 10.1016/j.clml.2018.10.001. doi: 10.1016/j.clml.2018.10.001 pmid: 30448048
[45]	Zinzani PL, Musuraca G, Tani M, et al. Phase Ⅱ trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma[J]. J Clin Oncol, 2007,25(27):4293-4297. DOI: 10.1200/JCO.2007.11.4207. doi: 10.1200/JCO.2007.11.4207 pmid: 17709797
[46]	Awasthi N, Schwarz MA, Schwarz RE. Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer[J]. HPB (Oxford), 2009,11(7):600-605. DOI: 10.1111/j.1477-2574.2009.00109.x. doi: 10.1111/j.1477-2574.2009.00109.x
[47]	Evens AM, Rosen ST, Helenowski I, et al. A phase Ⅰ/Ⅱ trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas[J]. Br J Haematol, 2013,163(1):55-61. DOI: 10.1111/bjh.12488. doi: 10.1111/bjh.12488 pmid: 23927371